Get the Stockscreener App
3.69
1.65%
0.06
Xenetic Biosciences Inc stock is traded at $3.69, with a volume of 67,597.
It is up +1.65% in the last 24 hours and up +34.67% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
See More
Previous Close:
$3.63
Open:
$3.63
24h Volume:
67,597
Relative Volume:
1.07
Market Cap:
$5.69M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-1.3418
EPS:
-2.75
Net Cash Flow:
$-4.11M
1W Performance:
-3.70%
1M Performance:
+34.67%
6M Performance:
-12.97%
1Y Performance:
-11.08%
1-Day Range:
$3.6101
$3.77
1-Week Range:
$3.49
$4.1383
52-Week Range:
$2.20
$5.2683
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.69 | 5.91M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Why Xenetic Biosciences Inc. stock attracts strong analyst attentionLow Risk High Reward Picks - Newser
What makes Xenetic Biosciences Inc. stock price move sharplyFree Exclusive Investment Tips - Newser
How Xenetic Biosciences Inc. stock performs during market volatilityFree Signals Group - Newser
Xenetic Biosciences (NASDAQ:XBIO) Shares Down 8% – What’s Next? - Defense World
Head to Head Comparison: Xenetic Biosciences (NASDAQ:XBIO) versus Vaxart (NASDAQ:VXRT) - Defense World
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C - Great Falls Tribune
New to The Street Announces Media Coverage of BitMine Immersion Technologies Inc., Including NewsOut Video PR Integration - Great Falls Tribune
North Shore Uranium Engages Investing News Network - Great Falls Tribune
LQR House Announces Strategic Marketing Cooperation with Montauk Distilling Co. for Cinnamon Flavored Rum - Great Falls Tribune
Monogram Technologies Announces the Mandatory Conversion of 8.00% Series D Convertible Cumulative Preferred Stock - Great Falls Tribune
Groundbreaking Pancreatic Cancer Trial Launches: DNase I Combined With FOLFIRINOX in Advanced Cases - Stock Titan
Unusual Machines Inc. Promotes Stacy Wright to Executive Vice President of Revenue as Company Scales U.S. Footprint and Prepares for Accelerated Growth - Great Falls Tribune
Why Did Cyclacel Pharmaceuticals Inc. (CYCC) Soar 13.92%? - AInvest
Xenetic Biosciences Reports Improved Q1 2025 Results - TipRanks
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World
Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World
Head-To-Head Survey: Xenetic Biosciences (NASDAQ:XBIO) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Equities Analysts Set Expectations for XBIO Q2 Earnings - Defense World
Xenetic Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Xenetic (XBIO) Reports Strong Revenue Growth for Q1 | XBIO Stock News - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial R - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Reports 16% Revenue Growth, Expands Cancer Drug Development with New Clinical Partnerships - Stock Titan
Xenetic Biosciences 2025 Q1 Earnings Loss Reduction as Net Income Improves by 24.4% - AInvest
Xenetic Biosciences: Q1 Earnings Snapshot - The Washington Post
Renaissance Technologies LLC Acquires 9,700 Shares of Xenetic Biosciences Inc (NASDAQ:XBIO) - Defense World
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - Barchart.com
Xenetic Biosciences Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Xenetic Biosciences, Inc. Announces Executive Leadership Transition - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Xenetic Biosciences (XBIO) to Release Earnings on Thursday - Defense World
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire
Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update - ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):